Head and neck sarcomas: the UCLA experience

Abstract Purpose To profile the clinical presentation, subtype distribution, and treatment results of sarcomas of the head and neck at a single tertiary academic center over an 11-year period. Materials and methods A retrospective review was performed by examining the records and reviewing the patho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of otolaryngology 2014-07, Vol.35 (4), p.476-481
Hauptverfasser: Tajudeen, Bobby A., MD, Fuller, Jennifer, MD, Lai, Chi, MD, Grogan, Tristan, MS, Elashoff, David, PhD, Abemayor, Elliot, MD, PhD, St. John, Maie, MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 481
container_issue 4
container_start_page 476
container_title American journal of otolaryngology
container_volume 35
creator Tajudeen, Bobby A., MD
Fuller, Jennifer, MD
Lai, Chi, MD
Grogan, Tristan, MS
Elashoff, David, PhD
Abemayor, Elliot, MD, PhD
St. John, Maie, MD, PhD
description Abstract Purpose To profile the clinical presentation, subtype distribution, and treatment results of sarcomas of the head and neck at a single tertiary academic center over an 11-year period. Materials and methods A retrospective review was performed by examining the records and reviewing the pathology of 186 patients with head and neck sarcomas treated at UCLA Medical Center from 2000 to 2011. Results The mean age of the study population was 49 ± 22 years. 58% of the patients were male and 42% were female. Median duration of follow-up for the entire group was 18.5 months. The most common presenting symptom was a mass lesion in 59.9% of patients. The nasal cavity/sinus was the most common presenting site seen in 22% of patients. Solitary fibrous tumor/hemangiopericytoma was the most common subtype. 15% of patients had evidence of prior radiation exposure. 26.3% of tumors were greater than 5 cm and 35.5% were high-grade. Margins were positive in 31.2% of patients. Lymph node metastasis was rare at 6.5%. Perineural invasion was identified in 6.5%. Among all subtypes, 5-year recurrence-free survival and overall survival were 50% and 49%, respectively. Multivariate analysis demonstrated that grade and margin status were predictors of recurrence-free survival while grade and age affected overall survival. Conclusions Head and neck sarcomas are a rare entity frequently presenting as a mass lesion. In our series, lesions tended to be high-grade with a significant portion of surgical specimens having positive margins. Grade and margin status were the most important predictors of survival.
doi_str_mv 10.1016/j.amjoto.2014.02.003
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4230788</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196070914000386</els_id><sourcerecordid>3332017931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c612t-97e90fb86d496d2c7e84c21179b53fdea5c97a856c25cf5a7d98da55d5f614b43</originalsourceid><addsrcrecordid>eNqFUk1v1DAUtBCILoV_gFAkLkgowXb8FQ5I1QpapJU4QCVuT177hTpN4sXOVvTfk3RLC71w8uHNjN_MG0JeMloxytS7rrJDF6dYccpERXlFaf2IrJiseWmY-f6YrChrVEk1bY7Is5w7OiNELZ-SIy40Z1qIFXl7htYXdvTFiO6yyDa5ONj8vpgusDhfb04K_LXDFHB0-Jw8aW2f8cXte0zOP338tj4rN19OP69PNqVTjE9lo7Gh7dYoLxrludNohOOM6WYr69ajla7R1kjluHSttNo3xlspvWwVE1tRH5MPB93dfjugdzhOyfawS2Gw6RqiDfDvZAwX8CNegeA11cbMAm9uBVL8ucc8wRCyw763I8Z9hjkjpQyTdIG-fgDt4j6Ns70FJamSmi0biQPKpZhzwvZuGUZhuQZ0cLgGLNcAymHOeqa9-tvIHelP_PdOcY7zKmCC7G6i9iGhm8DH8L8fHgq4PozB2f4SrzHfe4E8E-Dr0oilEEwsZTCq_g2pdbBd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1535065714</pqid></control><display><type>article</type><title>Head and neck sarcomas: the UCLA experience</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tajudeen, Bobby A., MD ; Fuller, Jennifer, MD ; Lai, Chi, MD ; Grogan, Tristan, MS ; Elashoff, David, PhD ; Abemayor, Elliot, MD, PhD ; St. John, Maie, MD, PhD</creator><creatorcontrib>Tajudeen, Bobby A., MD ; Fuller, Jennifer, MD ; Lai, Chi, MD ; Grogan, Tristan, MS ; Elashoff, David, PhD ; Abemayor, Elliot, MD, PhD ; St. John, Maie, MD, PhD</creatorcontrib><description>Abstract Purpose To profile the clinical presentation, subtype distribution, and treatment results of sarcomas of the head and neck at a single tertiary academic center over an 11-year period. Materials and methods A retrospective review was performed by examining the records and reviewing the pathology of 186 patients with head and neck sarcomas treated at UCLA Medical Center from 2000 to 2011. Results The mean age of the study population was 49 ± 22 years. 58% of the patients were male and 42% were female. Median duration of follow-up for the entire group was 18.5 months. The most common presenting symptom was a mass lesion in 59.9% of patients. The nasal cavity/sinus was the most common presenting site seen in 22% of patients. Solitary fibrous tumor/hemangiopericytoma was the most common subtype. 15% of patients had evidence of prior radiation exposure. 26.3% of tumors were greater than 5 cm and 35.5% were high-grade. Margins were positive in 31.2% of patients. Lymph node metastasis was rare at 6.5%. Perineural invasion was identified in 6.5%. Among all subtypes, 5-year recurrence-free survival and overall survival were 50% and 49%, respectively. Multivariate analysis demonstrated that grade and margin status were predictors of recurrence-free survival while grade and age affected overall survival. Conclusions Head and neck sarcomas are a rare entity frequently presenting as a mass lesion. In our series, lesions tended to be high-grade with a significant portion of surgical specimens having positive margins. Grade and margin status were the most important predictors of survival.</description><identifier>ISSN: 0196-0709</identifier><identifier>EISSN: 1532-818X</identifier><identifier>DOI: 10.1016/j.amjoto.2014.02.003</identifier><identifier>PMID: 24721744</identifier><identifier>CODEN: AJOTDP</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Age ; Bone cancer ; California - epidemiology ; Chemotherapy ; Disease-Free Survival ; Female ; Follow-Up Studies ; Head and Neck Neoplasms - epidemiology ; Head and Neck Neoplasms - pathology ; Humans ; Incidence ; Male ; Medical prognosis ; Metastasis ; Middle Aged ; Multivariate analysis ; Neoplasm Staging ; Otolaryngology ; Radiation therapy ; Retrospective Studies ; Sarcoma - epidemiology ; Sarcoma - pathology ; Studies ; Surgery ; Survival Rate - trends ; Tumors</subject><ispartof>American journal of otolaryngology, 2014-07, Vol.35 (4), p.476-481</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited 2014</rights><rights>2014 Elsevier Inc. All rights reserved. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c612t-97e90fb86d496d2c7e84c21179b53fdea5c97a856c25cf5a7d98da55d5f614b43</citedby><cites>FETCH-LOGICAL-c612t-97e90fb86d496d2c7e84c21179b53fdea5c97a856c25cf5a7d98da55d5f614b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0196070914000386$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24721744$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tajudeen, Bobby A., MD</creatorcontrib><creatorcontrib>Fuller, Jennifer, MD</creatorcontrib><creatorcontrib>Lai, Chi, MD</creatorcontrib><creatorcontrib>Grogan, Tristan, MS</creatorcontrib><creatorcontrib>Elashoff, David, PhD</creatorcontrib><creatorcontrib>Abemayor, Elliot, MD, PhD</creatorcontrib><creatorcontrib>St. John, Maie, MD, PhD</creatorcontrib><title>Head and neck sarcomas: the UCLA experience</title><title>American journal of otolaryngology</title><addtitle>Am J Otolaryngol</addtitle><description>Abstract Purpose To profile the clinical presentation, subtype distribution, and treatment results of sarcomas of the head and neck at a single tertiary academic center over an 11-year period. Materials and methods A retrospective review was performed by examining the records and reviewing the pathology of 186 patients with head and neck sarcomas treated at UCLA Medical Center from 2000 to 2011. Results The mean age of the study population was 49 ± 22 years. 58% of the patients were male and 42% were female. Median duration of follow-up for the entire group was 18.5 months. The most common presenting symptom was a mass lesion in 59.9% of patients. The nasal cavity/sinus was the most common presenting site seen in 22% of patients. Solitary fibrous tumor/hemangiopericytoma was the most common subtype. 15% of patients had evidence of prior radiation exposure. 26.3% of tumors were greater than 5 cm and 35.5% were high-grade. Margins were positive in 31.2% of patients. Lymph node metastasis was rare at 6.5%. Perineural invasion was identified in 6.5%. Among all subtypes, 5-year recurrence-free survival and overall survival were 50% and 49%, respectively. Multivariate analysis demonstrated that grade and margin status were predictors of recurrence-free survival while grade and age affected overall survival. Conclusions Head and neck sarcomas are a rare entity frequently presenting as a mass lesion. In our series, lesions tended to be high-grade with a significant portion of surgical specimens having positive margins. Grade and margin status were the most important predictors of survival.</description><subject>Age</subject><subject>Bone cancer</subject><subject>California - epidemiology</subject><subject>Chemotherapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Head and Neck Neoplasms - epidemiology</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Neoplasm Staging</subject><subject>Otolaryngology</subject><subject>Radiation therapy</subject><subject>Retrospective Studies</subject><subject>Sarcoma - epidemiology</subject><subject>Sarcoma - pathology</subject><subject>Studies</subject><subject>Surgery</subject><subject>Survival Rate - trends</subject><subject>Tumors</subject><issn>0196-0709</issn><issn>1532-818X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk1v1DAUtBCILoV_gFAkLkgowXb8FQ5I1QpapJU4QCVuT177hTpN4sXOVvTfk3RLC71w8uHNjN_MG0JeMloxytS7rrJDF6dYccpERXlFaf2IrJiseWmY-f6YrChrVEk1bY7Is5w7OiNELZ-SIy40Z1qIFXl7htYXdvTFiO6yyDa5ONj8vpgusDhfb04K_LXDFHB0-Jw8aW2f8cXte0zOP338tj4rN19OP69PNqVTjE9lo7Gh7dYoLxrludNohOOM6WYr69ajla7R1kjluHSttNo3xlspvWwVE1tRH5MPB93dfjugdzhOyfawS2Gw6RqiDfDvZAwX8CNegeA11cbMAm9uBVL8ucc8wRCyw763I8Z9hjkjpQyTdIG-fgDt4j6Ns70FJamSmi0biQPKpZhzwvZuGUZhuQZ0cLgGLNcAymHOeqa9-tvIHelP_PdOcY7zKmCC7G6i9iGhm8DH8L8fHgq4PozB2f4SrzHfe4E8E-Dr0oilEEwsZTCq_g2pdbBd</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Tajudeen, Bobby A., MD</creator><creator>Fuller, Jennifer, MD</creator><creator>Lai, Chi, MD</creator><creator>Grogan, Tristan, MS</creator><creator>Elashoff, David, PhD</creator><creator>Abemayor, Elliot, MD, PhD</creator><creator>St. John, Maie, MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140701</creationdate><title>Head and neck sarcomas: the UCLA experience</title><author>Tajudeen, Bobby A., MD ; Fuller, Jennifer, MD ; Lai, Chi, MD ; Grogan, Tristan, MS ; Elashoff, David, PhD ; Abemayor, Elliot, MD, PhD ; St. John, Maie, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c612t-97e90fb86d496d2c7e84c21179b53fdea5c97a856c25cf5a7d98da55d5f614b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Age</topic><topic>Bone cancer</topic><topic>California - epidemiology</topic><topic>Chemotherapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Head and Neck Neoplasms - epidemiology</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Neoplasm Staging</topic><topic>Otolaryngology</topic><topic>Radiation therapy</topic><topic>Retrospective Studies</topic><topic>Sarcoma - epidemiology</topic><topic>Sarcoma - pathology</topic><topic>Studies</topic><topic>Surgery</topic><topic>Survival Rate - trends</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tajudeen, Bobby A., MD</creatorcontrib><creatorcontrib>Fuller, Jennifer, MD</creatorcontrib><creatorcontrib>Lai, Chi, MD</creatorcontrib><creatorcontrib>Grogan, Tristan, MS</creatorcontrib><creatorcontrib>Elashoff, David, PhD</creatorcontrib><creatorcontrib>Abemayor, Elliot, MD, PhD</creatorcontrib><creatorcontrib>St. John, Maie, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of otolaryngology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tajudeen, Bobby A., MD</au><au>Fuller, Jennifer, MD</au><au>Lai, Chi, MD</au><au>Grogan, Tristan, MS</au><au>Elashoff, David, PhD</au><au>Abemayor, Elliot, MD, PhD</au><au>St. John, Maie, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Head and neck sarcomas: the UCLA experience</atitle><jtitle>American journal of otolaryngology</jtitle><addtitle>Am J Otolaryngol</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>35</volume><issue>4</issue><spage>476</spage><epage>481</epage><pages>476-481</pages><issn>0196-0709</issn><eissn>1532-818X</eissn><coden>AJOTDP</coden><abstract>Abstract Purpose To profile the clinical presentation, subtype distribution, and treatment results of sarcomas of the head and neck at a single tertiary academic center over an 11-year period. Materials and methods A retrospective review was performed by examining the records and reviewing the pathology of 186 patients with head and neck sarcomas treated at UCLA Medical Center from 2000 to 2011. Results The mean age of the study population was 49 ± 22 years. 58% of the patients were male and 42% were female. Median duration of follow-up for the entire group was 18.5 months. The most common presenting symptom was a mass lesion in 59.9% of patients. The nasal cavity/sinus was the most common presenting site seen in 22% of patients. Solitary fibrous tumor/hemangiopericytoma was the most common subtype. 15% of patients had evidence of prior radiation exposure. 26.3% of tumors were greater than 5 cm and 35.5% were high-grade. Margins were positive in 31.2% of patients. Lymph node metastasis was rare at 6.5%. Perineural invasion was identified in 6.5%. Among all subtypes, 5-year recurrence-free survival and overall survival were 50% and 49%, respectively. Multivariate analysis demonstrated that grade and margin status were predictors of recurrence-free survival while grade and age affected overall survival. Conclusions Head and neck sarcomas are a rare entity frequently presenting as a mass lesion. In our series, lesions tended to be high-grade with a significant portion of surgical specimens having positive margins. Grade and margin status were the most important predictors of survival.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24721744</pmid><doi>10.1016/j.amjoto.2014.02.003</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0196-0709
ispartof American journal of otolaryngology, 2014-07, Vol.35 (4), p.476-481
issn 0196-0709
1532-818X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4230788
source MEDLINE; Elsevier ScienceDirect Journals
subjects Age
Bone cancer
California - epidemiology
Chemotherapy
Disease-Free Survival
Female
Follow-Up Studies
Head and Neck Neoplasms - epidemiology
Head and Neck Neoplasms - pathology
Humans
Incidence
Male
Medical prognosis
Metastasis
Middle Aged
Multivariate analysis
Neoplasm Staging
Otolaryngology
Radiation therapy
Retrospective Studies
Sarcoma - epidemiology
Sarcoma - pathology
Studies
Surgery
Survival Rate - trends
Tumors
title Head and neck sarcomas: the UCLA experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T13%3A25%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Head%20and%20neck%20sarcomas:%20the%20UCLA%20experience&rft.jtitle=American%20journal%20of%20otolaryngology&rft.au=Tajudeen,%20Bobby%20A.,%20MD&rft.date=2014-07-01&rft.volume=35&rft.issue=4&rft.spage=476&rft.epage=481&rft.pages=476-481&rft.issn=0196-0709&rft.eissn=1532-818X&rft.coden=AJOTDP&rft_id=info:doi/10.1016/j.amjoto.2014.02.003&rft_dat=%3Cproquest_pubme%3E3332017931%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1535065714&rft_id=info:pmid/24721744&rft_els_id=S0196070914000386&rfr_iscdi=true